MYC Degradation
Open accessThe DOI matches its Crossref record; 111 of the 114 references it cites were found in a registry or an index.
Abstract
The MYC oncoprotein is an essential transcription factor that regulates the expression of many genes involved in cell growth, proliferation, and metabolic pathways. Thus, it is important to keep MYC activity in check in normal cells in order to avoid unwanted oncogenic changes. Normal cells have adapted several ways to control MYC levels, and these mechanisms can be disrupted in cancer cells. One of the major ways in which MYC levels are controlled in cells is through targeted degradation by the ubiquitin-proteasome system (UPS). Here, we discuss the role of the UPS in the regulation of MYC protein levels and review some of the many proteins that have been shown to regulate MYC protein stability. In addition, we discuss how this relates to MYC transcriptional activity, human cancers, and therapeutic targeting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We show that DT-061 binds a unique heterotrimeric regulatory pocket to selectively stabilize the B56α-PP2A holoenzyme thereby inducing cell death and attenuating tumor growth through B56α directed substrate dephosphorylation, including its most well characterized substrate, the oncogenic protein c-MYC (Allen-Petersen et al., 2018; Arnold and Sears, 2006; Farrell and Sears, 2014; Sheppard et al., 2”
From Selective PP2A enhancement through biased heterotrimer stabilization (2020) · cites this paper as Farrell and Sears, 2014
Citations
Cites
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Fraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., et al. (2005) · Nature Genetics · doi:10.1038/ng1531 · Cited by 1,923
A genomic and functional inventory of deubiquitinating enzymes.
Nijman, S. M. B., Luna-Vargas, M. P. A., Velds, A., Brummelkamp, T. R., Dirac, A. M. G., Sixma, T. K., & Bernards, R. (2005) · Cell · doi:10.1016/j.cell.2005.11.007 · Cited by 1,854
c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism
Dang, C. V. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.1 · Cited by 1,715
Max: A Helix-Loop-Helix Zipper Protein That Forms a Sequence-Specific DNA-Binding Complex with Myc
Blackwood, E. M., & Eisenman, R. N. (1991) · Science · doi:10.1126/science.2006410 · Cited by 1,697
Transcriptional Amplification in Tumor Cells with Elevated c-Myc
Lin, C. Y., Lovén, J., Rahl, P. B., Paranal, R. M., Burge, C. B., Bradner, J. E., Lee, T. I., & Young, R. A. (2012) · Cell · doi:10.1016/j.cell.2012.08.026 · Cited by 1,513
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability
Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K., & Nevins, J. R. (2000) · Genes & Development · doi:10.1101/gad.836800 · Cited by 1,393
Self-citationc-Myc Regulates Transcriptional Pause Release
Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010) · Cell · doi:10.1016/j.cell.2010.03.030 · Cited by 1,279
SCF and Cullin/RING H2-Based Ubiquitin Ligases
Deshaies, R. J. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.435 · Cited by 1,242
MYC oncogenes and human neoplastic disease
Nesbit, C. E., Tersak, J. M., & Prochownik, E. V. (1999) · Oncogene · doi:10.1038/sj.onc.1202746 · Cited by 1,158
Cited by
Items 301–400 of 471
Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells
Tang, M., Crown, J. P., & Duffy, M. J. (2023) · Investigational New Drugs · doi:10.1007/s10637-023-01368-1 · Cited by 8
Chen, G., Chen, S.-Y., Liu, S., Hsieh, C.-C., Lee, S., & Huang, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169137 · Cited by 13
“The phosphorylation at T58 of c-Myc is mediated by the processive kinase GSK3β [5,6].”
BackgroundInfluentialTorchia, M. L. G., & Ashwell, J. D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1813867115 · Cited by 11
Mödlhammer, A., Pfurtscheller, S., Feichtner, A., Hartl, M., & Schneider, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.660481 · Cited by 7
“To demonstrate that MYC degradation depends on the ubiquitin/proteasome pathway (40), kinetics were performed in presence of the proteasome inhibitor MG-132 (Figure 6C).”
MethodSUMOylation of SETD8 Promotes Tumor Growth by Methylating and Stabilizing MYC in Bladder Cancer
Zhang, X., Chen, Z., He, X., Wang, J., Zhong, J., Zou, Y., Zheng, X. F. S., Lin, Y., Zhang, R., Kang, T., et al. (2025) · Advanced Science · doi:10.1002/advs.202501734 · Cited by 12
Targeting the SYVN1-EGFR axis: a breakthrough strategy for TKI-resistant NSCLC
Xie, X., Tong, W., Xie, Y., Jiang, H., Jiang, A. Y. L., Huang, J., Liu, Z., & Yu, J. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07978-2 · Cited by 7
“The datasets generated in this study are available from the corresponding author upon reasonable request and will be provided in accordance with institutional guidelines.”
Abazari, N., Stefanucci, M. R., Bossi, L. E., Trojani, A., Cairoli, R., & Beghini, A. (2023) · Cancers · doi:10.3390/cancers15153931 · Cited by 8
“Previous studies reported that cordycepin induces protein degradation of β-catenin via GSK−3β signaling activation, promotes Cancers 2023, 15, 3931 10 of 14 leukemia apoptosis and eliminates leukemia stem cell activity [31–33,37].”
ResultA helicase-independent role of DHX15 promotes MYC stability and acute leukemia cell survival
Li, Q., Guo, H., Xu, J., Li, X., Wang, D., Guo, Y., Qing, G., Vlierberghe, P. V., & Liu, H. (2023) · iScience · doi:10.1016/j.isci.2023.108571 · Cited by 8
Hsiao, T., Wang, R., Lu, T., Shih, C.-H., Su, Y., Tsai, J., Jhan, P., Lia, C.-S., Chuang, H., Chang, K., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.649267 · Cited by 8
“In addition, many proteins are involved in the regulation of Myc protein stability and activity (Farrell and Sears, 2014), which might further interfere with c-Myc expression in myeloblasts in bone marrow specimens.”
BackgroundIdentification of the deubiquitinase USP28 as a novel molecular therapeutic target of ovarian cancer
Shen, J., Xie, M., Xu, Y., Qian, Q., Qiu, T., Shi, W., Ren, D., Ji, J., & Huang, J. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.11.055 · Cited by 8
Trim33 masks a non-transcriptional function of E2f4 in replication fork progression
Rousseau, V., Einig, E., Jin, C., Horn, J., Riebold, M., Poth, T., Jarboui, M. A., Flentje, M., & Popov, N. (2023) · Nature Communications · doi:10.1038/s41467-023-40847-0 · Cited by 9
“Several ubiquitin ligases target Myc for degradation but also regulate its function ina non-proteolyticmanner 18 .”
Gfi1 upregulates c-Myc expression and promotes c-Myc-driven cell proliferation
Zhang, Y., & Dong, F. (2020) · Scientific Reports · doi:10.1038/s41598-020-74278-4 · Cited by 7
A germline point mutation in the MYC-FBW7 phosphodegron initiates hematopoietic malignancies
Freie, B. W., Carroll, P. A., Varnum‐Finney, B., Ramsey, E. L., Ramani, V., Bernstein, I. D., & Eisenman, R. N. (2024) · Genes & Development · doi:10.1101/gad.351292.123 · Cited by 8
“Perhaps the most crucial region of the MYC protein required for this post-translational regulation is located in the transactivation domain in a conserved region known as MYC box I (for review, see Farrell and Sears 2014).”
SONG, J., Liu, W., Xiao, X., Song, J., Wang, C., Gajendran, B., Wei, X., Yang, C., Chen, Y., Yang, Y., et al. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119145 · Cited by 7
Mahani, A., Arvidsson, G., Sadeghi, L., Grandien, A., & Wright, A. P. H. (2021) · Cancers · doi:10.3390/cancers13236093 · Cited by 6
“MYC stability is affected by sequential phosphorylation at S62 and T58, where the former activates and stabilizes MYC, while subsequent phosphorylation at T58 primes MYC for proteasome-mediated degradation [13].”
BackgroundCLK3 promotes tumor proliferation by activating MYC signaling
Shen, J., Zhao, Y., Yang, M., & Sun, X. (2024) · Cell Division · doi:10.1186/s13008-024-00132-y · Cited by 6
“For example, c-Myc interacts with pathways such as Wnt/β-catenin, PI3K/AKT, and MAPK, influencing cellular behaviors such as proliferation, survival, and metastasis [15–17].”
BackgroundWang, H., Ma, B., Stevens, T., Knapp, J., Lu, J. L., & Prochownik, E. V. (2025) · Advanced Science · doi:10.1002/advs.202414601 · Cited by 7
Targeting MYC and BCL2 by a natural compound for “double‐hit” lymphoma
Liu, X., Xu, S., Zhang, J., Fan, M., Xie, J., Zhang, B., Li, H., Yu, G., Liu, Y., Zhang, Y., et al. (2022) · Hematological Oncology · doi:10.1002/hon.3010 · Cited by 5
Youn, E. K., Cho, H. M., Jung, J. K., Yoon, G.-E., Eto, M., & Kim, J. I. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114926 · Cited by 7
Oei, V., Chuang, L. S. H., Matsuo, J., Srivastava, S., Teh, M., & Ito, Y. (2023) · Communications Biology · doi:10.1038/s42003-023-05037-0 · Cited by 6
“…prolyl isomerase PIN1 facilitates protein phosphatase 2A (PP2A) in the dephosphorylation of phospho-S62; phosphorylation of MYC at T58 results in MYC ubiquitination by E3 ligase complex SKP1-CUL1-F-box/WD repeat-containing protein 7 (SCF Fbxw7 ) and subsequent degradation by 26S proteasome 4,37 .”
Reciprocal regulation of lncRNA MEF and c-Myc drives colorectal cancer tumorigenesis
Wu, S., Dai, X., Zhu, Z., Fan, D., Jiang, S., Dong, Y., Chen, B., Xie, Q., Yao, Z., Li, Q., et al. (2024) · Neoplasia · doi:10.1016/j.neo.2024.100971 · Cited by 7
“The existence of a lncRNA-mediated positive feedback loop is noteworthy because of the requirement for c-Myc expression to be tightly regulated through transcriptional and posttranscriptional mechanisms, particularly in normal cells [9,41].”
BackgroundTargeting Myc: Is It Getting Any Easier?
Zinzalla, G. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0119 · Cited by 6
Bauer, T. M., Dhir, T., Strickland, A. G., Thomsett, H. L., Goetz, A. B., Cannaday, S., Brody, J. R., Pishvaian, M. J., & Yeo, C. J. (2018) · Journal of Pancreatic Cancer · doi:10.1089/pancan.2018.0015 · Cited by 6
Ubiquitylation of unphosphorylated c-myc by novel E3 ligase SCFFbxl8
Bajpai, S., Jin, H. R., Mucha, B., & Diehl, J. A. (2022) · Cancer Biology & Therapy · doi:10.1080/15384047.2022.2061279 · Cited by 6
“Highlighting the importance of this degradation pathway in cancer, many of the signaling proteins implicated in the MYC S62/T58 phosphorylation are often deregulated in tumor cells, resulting in altered c-myc phosphorylation and increased c-myc protein stability.(5,7) In this study, we describe the identification and…”
BackgroundPeripubertal high‐fat diet promotes c‐Myc stabilization in mammary gland epithelium
Kulathunga, N., Kohno, S., Linn, P., Nishimoto, Y., Horike, S., Зарайский, М. И., Kumar, S., Muranaka, H., & Takahashi, C. (2020) · Cancer Science · doi:10.1111/cas.14492 · Cited by 4
Zhai, W., Yang, W., Ge, J., Xiao, X., Wu, K., She, K., Zhou, Y., Kong, Y., Wu, L., Luo, S., et al. (2024) · Biology Direct · doi:10.1186/s13062-024-00512-y · Cited by 6
ATE1 promotes breast cancer progression via arginylation-dependent regulation of MAPK-MYC signaling
Nawale, L., Ju, S., Kim, J. G., Soung, N., Kim, B. Y., Lee, C., & Cha‐Molstad, H. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02376-9 · Cited by 5
“In contrast, subsequent phosphorylation at Thr58 by glycogen synthase kinase 3β (GSK-3β) destabilizes MYC through Fbw7 E3 ligase-mediated ubiquitylation of MYC p-Thr58 [40, 41].”
Heterobifunctional proteomimetic polymers for targeted degradation of MYC and KRAS
Wang, M. M., Truica, M. I., Gattis, B. S., Oktawiec, J., Sagar, V., Basu, A. A., Bertin, P. A., Zhang, X., Abdulkadir, S. A., & Gianneschi, N. C. (2026) · Nature Communications · doi:10.1038/s41467-026-68913-3 · Cited by 9
“Unlike a stoichiometric mechanism that requires continuous compound presence, a catalytic process is consistent with the sustained target suppression observed even after compound removal 50 .”
Identification of microbial metabolites that accelerate the ubiquitin-dependent degradation of c-Myc
Liu, Z. L., Okano, A., Sanada, E., Futamura, Y., Nogawa, T., Ishikawa, K., Semba, K., Li, J., Li, X., Osada, H., et al. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.030248 · Cited by 5
“The ubiquitin-proteasome pathway is the major pathway through which c-Myc levels are controlled [18,19].”
Zhu, Y., Liu, Y., Wang, X., Chen, Z., Chen, B., Hu, B., Tang, T., Cheng, H., Liu, X., & Ning, Y. (2025) · Advanced Science · doi:10.1002/advs.202413120 · Cited by 7
Ding, L. J., Ni, W., Ma, Y., Xu, L., Zhang, Z., Liao, K., Li, J., Mei, X.-Y., Wang, Z., Ge, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202502416 · Cited by 5
MYC: The Guardian of Its Own Chaos
Gaballa, A., Krenz, B., & Uhl, L. (2025) · BioEssays · doi:10.1002/bies.70010 · Cited by 6
“Phosphorylation of S62, mainly by ERK, stabilizes MYC, whereas GSK3 β -dependent phosphorylation of T58 destabilizes MYC by recruiting FBW7, which mediates its ubiquitination leading to proteasomal degradation [18, 19, 51].”
High-Throughput Sequencing Reveals Transcriptome Signature of Early Liver Development in Goat Kids
Zhao, X., Xuan, R., Wang, A., Li, Q., Zhao, Y., Du, S., Duan, Q., Wang, Y., Ji, Z., Guo, Y., et al. (2022) · Genes · doi:10.3390/genes13050833 · Cited by 5
“The oncoprotein MYC is an important transcription factor that regulates the growth, proliferation, and expression of genes involved in different cellular signaling pathways [60].”
BackgroundBafetinib Suppresses the Transcription of PD-L1 Through c-Myc in Lung Cancer
Chen, X., Du, Q., Guo, H., He, Q., Yang, B., & Ding, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.897747 · Cited by 6
“The stability of c-Myc depends on p-c-Myc (S62) and p-cMyc (T58), which regulate the transcriptional activity of c-Myc (Farrell et al., 2013; Farrell and Sears, 2014).”
BackgroundFan, L., Wang, X., Cheng, C., Wang, S., Li, X., Cui, J., Zhang, B., & Shi, L. (2023) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2023/1307323 · Cited by 6
“c-Myc, a transcription factor, plays a signifcant role in cell transformation and cell proliferation regulation, diferentiation, and apoptosis [73, 74], and it has also been identifed to play a critical role in promoting the metastasis of NSCLC [75].”
BackgroundAcetylation of c-Myc at Lysine 148 Protects Neurons After Ischemia
Guzenko, V., Bachurin, S. S., Dzreyan, V., Khaitin, A. M., Kalyuzhnaya, Y. N., & Demyanenko, S. V. (2024) · NeuroMolecular Medicine · doi:10.1007/s12017-024-08777-2 · Cited by 5
“…with its partners and enzyme recruitment (Kumar et al., 2017). c-Myc as well as its activity are related to its post-translational modifications via acetylation or methylation (Farrell & Sears, 2014), which have not been previously studied at non-oncogenic level, let alone in models of ischemia.”
Madduri, L. S. V., Brandquist, N. D., Palanivel, C., Talmon, G. A., Baine, M. J., Zhou, S., Enke, C. A., Johnson, K. R., Ouellette, M. M., & Yan, Y. (2021) · Neoplasia · doi:10.1016/j.neo.2021.10.002 · Cited by 5
Hayes, T. K., & Der, C. J. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1806-1_6 · Cited by 9
Deconstructing Pancreatic Adenocarcinoma by Targeting the Conductor, MYC
English, I. A., & Sears, R. C. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0046 · Cited by 5
Self-citationMohiuddin, I. S., Wei, S., Yang, I., Martinez, G. M., Yang, S., Cho, E. J., Dalby, K. N., & Kang, M. H. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27712 · Cited by 5
“It is a transcription factor with a short half‐life, and its expression is low and tightly expressed in normal cells (Dang, 2013; Farrell & Sears, 2014).”
BackgroundCancer Metabolism Historical Perspectives: A Chronicle of Controversies and Consensus
Dang, C. V. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041530 · Cited by 9
“In this context, it should be noted that the RAS-ERK pathway has been shown to increase Myc expression and protein levels (Farrell and Sears 2014).”
Chen, S., Liao, Z., Mo, J., Liu, F., Wang, W., Zhang, H., Zhang, H., Liu, Y., Pan, Y., Zhu, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64079-6 · Cited by 7
“The expression of MYC is intricately regulated by the ubiquitin-proteasome system 17 .”
Eskandari, N., Delisi, D., O’Neil, R. T., Bocchetta, M., & Gentile, S. (2025) · Communications Biology · doi:10.1038/s42003-025-08917-9 · Cited by 4
“The canonicalc-MycdegradationsignalingrequiresubiquitinationbytheF-Box andWDRepeatDomainContaining7(FBXW7)E3ubiquitinligasesupon phosphorylation of Thr-58 11 .”
PAK4 phosphorylates and stabilizes MYC to promote acute myeloid leukemia
Xie, T., Sun, P., Huang, H., Li, Q., Liu, H., & Jiang, J. (2025) · Cell Insight · doi:10.1016/j.cellin.2025.100274 · Cited by 4
“FBXW7 is the primary E3 ligase responsible for MYC proteasomal degradation (Farrell and Sears, 2014; Yeh et al., 2018), and its depletion abrogated MYC downregulation in PAK4 -knockdown HL60 and OCI-AML3 cells (Fig.”
Tokugawa, M., Inoue, Y., Aoki, H., Miyajima, C., Ishiuchi, K., Tsurumi, K., Kujirai, C., Morishita, D., Matsuno, M., Mizukami, H., et al. (2023) · The Journal of Biochemistry · doi:10.1093/jb/mvad085 · Cited by 4
AF1q is a universal marker of neuroblastoma that sustains N-Myc expression and drives tumorigenesis
Oskouian, B., Lee, J. Y., Asgharzadeh, S., Khan, R., Zhang, M., Weisbrod, J. R., Choi, Y., Puri, L., Aguilar, A. E., Zhao, P., et al. (2024) · Oncogene · doi:10.1038/s41388-024-02980-y · Cited by 3
“The normally short half-life of N-Myc (~30 m) is due to its ubiquitination which targets it for degradation by the proteasome [31].”
BackgroundSTK16 promoted colorectal cancer progress in a c-MYC signaling-dependent manner
Peng, L., Liu, G., Wusman, L. B., & Li, T. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00816-9 · Cited by 4
Reversible downregulation of MYC in a spheroid model of metastatic epithelial ovarian cancer
Buensuceso, A. V., Borrelli, M. J., Valdés, Y. R., & Shepherd, T. G. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00850-z · Cited by 6
“In particular, phosphorylation of MYC at Thr58 is associated with proteasomal degradation, while phosphorylation at Ser62 is associated with increased stability and transcriptional activity [27].”
Ondroušková, E., Michaela, B., Závacká, K., Čech, P., Šmuhařová, P., Boudný, M., Oršulová, M., Panovská, A., Radová, L., Doubek, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.859618 · Cited by 4
Xiang, W., Ni, J., Dong, L., & Zhu, G. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102415 · Cited by 4
Enhancing c-MYC degradation via 20S proteasome activation induces in vivo anti-tumor efficacyPreprint
Njomen, E., Lansdell, T. A., Vanecek, A. S., Benham, V., Bernard, M. P., Yang, Y.-T., Schall, P. Z., Isaac, D., Alkharabsheh, O. A., Al-Janadi, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.24.265470 · Cited by 4
Human SIRT5 variants with reduced stability and activity do not cause neuropathology in mice
Yuan, T., Kumar, S., Skinner, M. E., Victor-Joseph, R., Abuaita, M., Keijer, J., Zhang, J., Kunkel, T. J., Liu, Y., Petrunak, E. M., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109991 · Cited by 5
MYC amplification sensitizes TNBC to CHK1 inhibitors
Li, B., Liu, T., Zhao, M., Guo, D., Peng, W., Tao, Z., Hu, X., & Jin, J. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111709 · Cited by 4
From non‐coding RNAs to cancer regulators: The fascinating world of micropeptides
Li, C., Zhang, D., Huang, J., He, Z., Song, T., Wang, X., Kong, Q., Li, L., Liu, Z., Zhang, N., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.35459 · Cited by 5
Kral, A. J., Jia, L., Sim, G., Wan, L., Ishigami, Y., & Krainer, A. R. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.12.004 · Cited by 9
CDK2 inhibition promotes neuronal differentiation in neuroblastoma
Alzrigat, M., Mahmoud, L., Topçu, A. N., Valenti, M., Zhang, L., Veen, P., John, F. C., Bazzar, W., Lehti, K., & Larsson, L.-G. (2026) · Scientific Reports · doi:10.1038/s41598-026-38123-4 · Cited by 3
“…(and induced stabilization) is very transient and rapidly results in phosphorylation of Thr-58 and subsequent FBXW7-mediated degradation, depending on the status of FBXW7, the GSK3β kinase (phosphorylating Thr-58) and phosphatases and de-ubiquitination enzymes acting at these sites 75 .”
Moraleva, A. A., Антипова, Н. В., Pavlov, P., Dobrochaeva, K. L., & Rubtsov, Y. P. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1749992 · Cited by 5
“C-myc has short half-life, between 20 and 30 min, due to rapid degradation by ubiquitin-proteasome system (Thomas and Tansey, 2011; Farrell and Sears, 2014; Ahmadi et al., 2021).”
Aurora B facilitates cholangiocarcinoma progression by stabilizing c‐Myc
Liu, K., Zhou, X., Huang, F., Liu, L., Xu, Z., Gao, C., Zhang, K., Hong, J., Yao, N., & Cheng, G. (2024) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12370 · Cited by 3
“51 This study highlights Aurora B as a potential therapeutic target for CCA.”
BackgroundT-cell Dysfunction upon Expression of MYC with Altered Phosphorylation at Threonine 58 and Serine 62
Daniel, C. J., Pelz, C., Wang, X., Munks, M. W., Ko, A., Murugan, D., Byers, S. A., Juarez, E., Taylor, K. L., Fan, G., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0560 · Cited by 4
Self-citationFunctional Roles of the lncRNA MALAT1 in Glioma
Moftakhar, A., Najafi, S., Anbiyaee, O., Farzaneh, M., & Khoshnam, S. E. (2023) · Current Cancer Therapy Reviews · doi:10.2174/1573394719666230720164009 · Cited by 4
Chai, D., Yang, C., Liu, Y., Li, H., Lian, B., Bai, Z., & Li, J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20651 · Cited by 3
The Selective SIRT3 Inhibitor 3-TYP Represses Primary Myeloma Growth by Reducing c-Myc Stability
Zeng, Y., Zhang, Y., Cui, Z., Mao, J., Xu, J., & Yao, R. (2024) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.4c00142 · Cited by 3
ARMCX1 inhibits lung adenocarcinoma progression by recruiting FBXW7 for c-Myc degradation
Hu, Z., Wu, Y., Sun, X., Tong, Y., Qiu, H., & Zhuo, E. (2024) · Biology Direct · doi:10.1186/s13062-024-00532-8 · Cited by 3
“The GraphPad Prism 8 software and SPSS Statistics 25 were applied for the statistical analyses.”
BackgroundMethodFAM49B drives colorectal cancer progression by stabilizing c‐Myc through NEK9 phosphorylation
Chen, L., Liu, T., Yimin, E., Miao, L., Yu, C., Zhang, J., & Luo, X. (2025) · BioFactors · doi:10.1002/biof.2158 · Cited by 3
In silico modeling of phosphorylation dependent and independent c-Myc degradation
Chakravorty, D., Banerjee, K., Mapder, T., & Saha, S. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2846-x · Cited by 3
“for degradation in the proteasome [15].”
BackgroundRobles, M. T. S., Chong, J.-L., Koivisto, C. S., Trimboli, A. J., Liu, H., Leone, G. W., & Pipas, J. M. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0166 · Cited by 3
“Other pathways, such as rapid protein degradation, can control c-myc independently of b-catenin nuclear localization (39).”
Shang, C., Lai, J. Y. Q., Haque, M., Chen, W., Wang, P., & Lai, R. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814337 · Cited by 2
The ubiquitin ligase NKLAM promotes apoptosis and suppression of cell growth
Willard, P. A., & Kornbluth, J. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108527 · Cited by 2
“It is well documented that c-Myc is degraded in a proteasome-dependent manner (32), so we investigated this process in the presence of NKLAM.”
Wang, D., Wang, X., Li, W., Liang, C.-H., Zou, Y.-X., Xiao, J.-W., Kang, Q., Wang, J., Mao, L., Chen, J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.036 · Cited by 5
García‐Castillo, J., Martínez, C. M., Bernabé‐García, M., Munítiz, V., de Angulo, D. R., Parrilla, P., Ortiz, Á., de Haro, L. F. M., & Cayuela, M. L. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70048 · Cited by 4
“The level and activity of c-MYC protein are mainly controlled and regulated by ubiquitination and deubiquitination and are mediated by a number of ubiquitin ligases and deubiquitinating enzymes [29].”
Ren, Y.-Z., Zhao, M.-N., Du, F.-L., Wu, L., Wang, L., & Lou, J.-T. (2026) · Oncogene · doi:10.1038/s41388-026-03687-y · Cited by 2
The c-Myc-USP14-PFKP axis sustains chemoresistance in pancreatic ductal adenocarcinoma
Wang, P., Guo, W., Yang, Y., Xie, Y., Yin, F., Li, J., Shi, X., 曹佩, Ma, C., Ding, B., et al. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101385 · Cited by 3
Carbone, F. P., Hanau, S., & Bianchi, N. (2026) · Non-Coding RNA · doi:10.3390/ncrna12020011 · Cited by 4
“LncRNA-MIF exemplifies how a single lncRNA can integrate transcriptional regulation, miRNA interaction, and protein turnover to fine-tune cancer energy metabolism and support metabolic adaptation under oncogenic stress [137,139,140].”
Targeted O-GlcNAcylation enables functional rewiring of c-Myc
Xu, T., Guo, Z., Khan, K. S., Huang, Y., Ma, B., Ji, S., Liu, J., Felsher, D. W., & NG, B. K. W. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.08.008 · Cited by 2
Wang, X., Shen, Y., Chen, Y., & Yang, S. (2024) · Advances in Biomarker Sciences and Technology · doi:10.1016/j.abst.2024.06.002 · Cited by 2
Shi, S., Li, X., Alderman, C., Wick, L., Huang, W., Foulon, N., Zhang, L., Rossi, J. J., Hu, W., Cui, S., et al. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110287 · Cited by 2
Proteasome Activator 28γ: Impact on Survival Signaling and Apoptosis
Stohwasser, R. (2018) · InTech eBooks · doi:10.5772/intechopen.74731 · Cited by 2
MYC degradation via AURKB inhibition: a new brake in the path to T-ALL
Zhang, W., & Pear, W. S. (2020) · Blood Science · doi:10.1097/bs9.0000000000000046 · Cited by 2
Ruan, Y., Kim, H. N., Ogana, H. A. N., Wan, Z., Hurwitz, S., Nichols, C. M., Abdel‐Azim, N., Coba, A., Seo, S., Loh, Y. E., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.766888 · Cited by 2
“Decrease in c-Myc protein expression could be restored by the proteasome inhibitor MG132, which shows c-Myc degradation in B-ALL occurs through the ubiquitin-proteasome pathway (26) (Figure 1E, Figure S3B).”
BackgroundChen, K., Zhang, M., Fan, L., & Wang, Z. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/8823231 · Cited by 4
“MYC is a multifunctional transcription factor that can regulate the expression of many genes involved in biological processes such as cell growth, proliferation, apoptosis, and metabolism [37].”
BackgroundBRD4 as a potential target for human papillomaviruses associated cancer
Rani, A. Q., Bonam, S. R., Zhou, J., Li, J., Hu, H., & Liu, X. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29294 · Cited by 2
Dohmen, R. J. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1062331 · Cited by 2
Zhang, D., Zhang, X., Zhang, X., Zhao, Y., & Zhang, L. (2025) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2025.111902 · Cited by 3
Wei, J., Liu, J., Zhang, Y., Wang, G., Cui, X., Yu, W., Nie, C., & Hou, P. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.111224 · Cited by 1
“The MBI domain of c-Myc contains two crucial phosphorylation sites, Ser62 and Thr58 [28].”
InfluentialPPDPF promotes the progression of esophageal squamous cell carcinoma via c-Myc/CD24 axis
Zhu, B., Ma, N., Liu, Z., Zheng, Q., Liang, X., Chen, Y., Wang, Y., Cao, H., Xia, J., Xu, S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012044 · Cited by 3
RPL22L1-Myc positive feedback loop drives lung adenocarcinoma progression
Wu, Y., Zhu, Y., Jiang, R., Gu, W., Lu, L., Yao, N., Du, B., & Lai, J. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03945-1 · Cited by 1
“Myc is a very unstable protein with a short half-life, and the ubiquitin-proteasome system is one of the keys to regulating Myc protein stability [16, 39].”
A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression
Sriratanasak, N., Nutho, B., Wattanathana, W., Phaonakrop, N., Panasawatwong, B., Erlenbach‐Wuensch, K., Roytrakul, S., Schneider‐Stock, R., & Chanvorachote, P. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70127 · Cited by 1
“Under normal conditions, the c-Myc protein has a short half-life of at most 20 – 30 min [8].”
Akhlaghipour, I., & Moghbeli, M. (2025) · Cancer Cell International · doi:10.1186/s12935-025-04076-3 · Cited by 3
“C-Myc stability is modulated by several E3 ubiquitin ligases [118], and the SCF-Fbxw7 complex is a well-recognized E3 ligase associated with c-Myc.”
Targeting USP28 inhibits clear cell renal cell carcinoma growth
Ren, Y., Yang, Y., Zhu, X., Li, L., Pan, Y., Sun, H., Fang, Q., Xiong, H., Guo, D., Sun, Y., et al. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.112344 · Cited by 3
Demyanenko, S. V., Khaitin, A. M., & Batalshchikova, S. A. (2026) · Biochemistry (Moscow) Supplement Series A Membrane and Cell Biology · doi:10.1134/s1990747825700515 · Cited by 1
“The level of c-Myc, as well as its activity, is associated with its PTM via acetylation or methylation [22].”
The GFPT2/O-GlcNAcylation/c-Myc axis promotes bladder cancer progression
Xie, H., 廖恬菱, Tang, H., Ban, C., Cheng, Z., Liao, K., Li, Y., Wei, W., Zhou, L. Q., & Yi, X. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07811-0 · Cited by 1
“Previous studies have demonstrated that c-Myc stability is regulated by ubiquitination [32, 33].”
WEE1 stabilizes MYC to promote therapeutic resistance in esophageal adenocarcinoma
Thangaretnam, K., Islam, M. O., Lv, J., Zhang, Z., Chen, L., 姚, 慧., Lu, H., 彭敦发, Zaika, A., El‐Rifai, W., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218418 · Cited by 1
Fu, Z., Shi, R., Jiang, L., Zhang, W., Liu, Y., Chen, W., Zhu, F., Chen, R., Jin, G., Chen, Y., et al. (2026) · Cell investigation. · doi:10.1016/j.clnves.2026.100078 · Cited by 3
lnc122 RNA prevents liver tumorigenesis in MYC-driven liver cancer
Jang, H., Zhang, F., Suh, B. K., Le, A., Stephens, C. J., Casey, K. M., & Kay, M. A. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101916 · Cited by 1
“33,34 Alterations in the expression or function of MYC E3 ubiquitin li-gases for MYC protein degradation have been reported in various types of cancer.”
Epidermal stem cells participate in the repair of scalds via Nanog and Myc regulation
Yin, D., Zhang, X., Jiang, Q., Luo, S., Luo, Y., Cheng, P., Jin, G., & Liu, C. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12881 · Cited by 1
Ubiquitin–Proteasome System in the Induction and Maintenance of Cellular Pluripotency
Zubarev, I. V., Podenkova, U. I., Tomilin, A. N., & Цимоха, А. С. (2022) · Russian Journal of Developmental Biology · doi:10.1134/s1062360422060091 · Cited by 1
“Ubiquitination and proteolysis are important for regulating the stability and proper functioning of c-Myc. c-Myc is known to have a short half-life, which is regulated by UPS (Farrell and Sears, 2014).”
BackgroundRegulation of Gene Expression by the MYC Transcription Factor Network During Exercise
Astratenkova, I. V., Golberg, N. D., & Rogozkin, V. A. (2023) · Human Physiology · doi:10.1134/s036211972360011x · Cited by 1
Computational completion of the Aurora interaction region of N-Myc in the Aurora a kinase complex
Altıner, P., Çınaroğlu, S. S., Timuçin, A. C., & Timuçin, E. (2023) · Scientific Reports · doi:10.1038/s41598-023-45272-3 · Cited by 1
Huang, Q., Ye, B., Ye, Z., Huang, S., Xue, J., Cui, F., Jiang, T., Sun, L., Zeng, Y., Wang, S., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0332277 · Cited by 1
“…elements, governing gene transcription by modulating RNA polymerase activity [7]. c-Myc, a prototypical transcription factor of the Myc gene family [8], exerts pleiotropic roles in cellular processes, including the regulation of proliferation, differentiation, apoptosis, and metabolism [9].”
Identifying and Validating MYC:Protein Interactors in Pursuit of Novel Anti-MYC Therapies
Resetca, D., MacDonald, A. S., Kenney, T. M. G., Wei, Y., Arrowsmith, C. H., Raught, B., & Penn, L. Z. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1476-1_4 · Cited by 2
Metadata
- Authors
- Farrell, A. S., & Sears, R. C.
- Affiliations
- Oregon Health & Science University (US)
- ORCID
- Sears, R. C.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-03-01
- Volume
- 4
- Issue
- 3
- Pages
- a014365-a014365
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3935390
- OpenAlex
- W4236967220
- Cited by
- 468
- References
- 114
- Citations by year
- 2026: 35 · 2025: 38 · 2024: 46 · 2023: 58 · 2022: 58 · 2021: 53 · 2020: 55 · 2019: 29 · 2018: 28 · 2017: 17 · 2016: 20 · 2015: 17 · 2014: 10
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- Myc oncoprotein, protein degradation, ubiquitin-proteasome system, MYC protein stability, transcriptional regulation, cancer, MYC-targeted therapy, cell proliferation
- MeSH terms
- Acetylation, Cell Communication, Humans, Neoplasms, Transcription, Genetic, Genes, myc, Ubiquitin, Proteasome Endopeptidase Complex, Protein Stability, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.